靶向B7-H3的实体瘤免疫治疗新进展  

New progress in immunotherapy of solid tumors targeting B7-H3

作　　者：吴硕 贺炜 胡鹏武 惠开元 江艳婷 蒋晓东[1,2] Shuo Wu;Wei He;Pengwu Hu;Kaiyuan Hui;Yanting Jiang;Xiaodong Jiang(Department of Radiation Oncology,Lianyungang Clinical Medical College of Nanjing Medical University,Lianyungang 222000,China;Department of Radiation Oncology,The Affiliated Lianyungang Hospital of Xuzhou Medical University,Lianyungang 222000,China)

机构地区：[1]南京医科大学连云港临床医学院放疗科,江苏省连云港市222000 [2]徐州医科大学附属连云港医院放疗科

出　　处：《中国肿瘤临床》2024年第24期1291-1295,共5页Chinese Journal of Clinical Oncology

摘　　要：B7H3作为免疫球蛋白超家族B7家族的成员,在肿瘤组织中异常表达,可被免疫细胞诱导表达,而在正常组织中低表达或不表达。B7-H3以诱导肿瘤恶性行为并通过多种复杂途径推动癌症进展的特性受到关注。以B7-H3为靶点的免疫疗法通过改变免疫系统增强抗肿瘤免疫反应,在临床试验中展示出显著疗效。本文梳理B7-H3在人体各种系统肿瘤中的异常表达及其影响,并总结B7-H3在免疫治疗中的角色,以此反映出靶向B7-H3的临床研究新进展。这些发现表明,B7-H3具有作为未来肿瘤诊断和治疗靶点的巨大价值。B7-H3,a member of the B7 family within the immunoglobulin superfamily,is aberrantly expressed in tumor tissues and can be induced by immune cells,but is minimally expressed or not expressed in normal tissues.B7-H3 has gained attention for its ability to induce malignant behaviors in tumors and promote cancer progression through various complex pathways.Immunotherapy targeting B7-H3 has shown significant efficacy in clinical trials by modulating the immune system to enhance anti-tumor immune responses.We comprehensively summarize the abnormal expression and impact of B7-H3 in various human tumor types,and its role in immunotherapy,highlighting recent advances in clinical research targeting B7-H3.These findings suggest that B7-H3 holds great value as a future target for cancer diagnosis and treatment.

关 键 词：B7-H3 免疫治疗 实体瘤 联合治疗 综述 

分 类 号：R730.51[医药卫生—肿瘤]